ERBB2 and neoplasm: Participant AER8 was diagnosed with an ER+/progesterone receptor (PR)+/HER2– LumA subtype primary tumor and received neoadjuvant chemotherapy and adjuvant endocrine therapy plus everolimus; participant AER8 was diagnosed with liver metastases after ~20 months of treatment, received an additional three lines of therapy and succumbed to disease, at which time biopsies of several metastatic lesions were obtained (Fig. 6a).